Slides

Add Search Results to Slide Tray Search:

"pulmonary exacerbation"

Slides: 1–4 of 4

Add to tray Remove from tray

Clinical Questions Addressed by the CER (1)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: intermediate outcomes | health outcomes | pulmonary function | body composition | bone mineralization | pulmonary exacerbation | mortality risk | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH

Add to tray Remove from tray

rhGH Effects on Health Outcomes Reported in Controlled Trials

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Keywords: hospitalization | rate | pulmonary | exacerbation | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH

$This slide shows an analytic framework for a CER on the use of recombinant human growth hormone in patients with cystic fibrosis. The population with cystic fibrosis, including subgroups (age, gender, baseline clinical status, prior treatment) receives recombinant human growth hormone. The intermediate outcomes include IGF factors, protein turnover, nutritional status, growth measures, bone measures, lung function, pulmonary exacerbations, antibiotic use, exercise tolerance, sex hormones, and pubertal development. The final health outcomes include mortality, hospitalization, bone fracture, and health-related quality of life. The adverse events include altered glucose, diabetes mellitus, lymphoid overgrowth, and malignancy.$

Add to tray Remove from tray

Devise an Analytic Framework

Presentation: Topic Refinement

Keywords: analytic framework | PICOTS framework | health outcomes | intervention | direct evidence

$Topic Refinement Process: UCONN/HH EPC Example (IV). This slide shows an analytic framework for a CER on the use of recombinant human growth hormone in patients with cystic fibrosis. The population with cystic fibrosis, including subgroups receiving recombinant human growth hormone. The intermediate outcomes include IGF factors, protein turnover, nutritional status, growth measures, bone measures, lung function, pulmonary exacerbations, antibiotic use, exercise tolerance, sex hormones, and pubertal development. The final health outcomes include mortality, hospitalization, bone fracture, and health-related quality of life. The adverse events include altered glucose, diabetes mellitus, lymphoid overgrowth, and malignancy.$

Add to tray Remove from tray

Topic Refinement Process: UCONN/HH EPC Example (IV)

Presentation: Topic Refinement

Keywords: topic refinement | analytic framework | comparative effectiveness review | population | outcome | intervention | comparator | PICOTS framework